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Introduction: HFE p.C282Y homozygosity is the most
common cause of hereditary haemochromatosis. There
is currently insufficient evidence to assess whether
non-specific symptoms or hepatic injury in
homozygotes with moderately elevated iron defined as
a serum ferritin (SF) of 300–1000 µg/L are related to
iron overload. As such the evidence for intervention in
this group is lacking. We present here methods for a
study that aims to evaluate whether non-specific
symptoms and hepatic fibrosis markers improve with
short-term normalisation of SF in p.C282Y
homozygotes with moderate elevation of SF.
Methods and analysis: Mi-iron is a prospective,
multicentre, randomised patient-blinded trial conducted
in three centres in Victoria and Queensland, Australia.
Participants who are HFE p.C282Y homozygotes with
SF levels between 300 and 1000 μg/L are recruited and
randomised to either the treatment group or to the
sham treatment group. Those in the treatment
group have normalisation of SF by 3-weekly
erythrocytapheresis while those in the sham treatment
group have 3-weekly plasmapheresis and thus do not
have normalisation of SF. Patients are blinded to all
procedures. All outcome measures are administered
prior to and following the course of treatment/sham
treatment. Patient reported outcome measures are the
Modified Fatigue Impact Scale (MFIS-primary
outcome), Hospital Anxiety and Depression Scale
(HADS), Medical Outcomes Study 36-item short form
V.2 (SF36v2) and Arthritis Impact Measurement Scale
2 short form (AIMS2-SF). Liver injury and hepatic
fibrosis are assessed with transient elastography (TE),
Fibrometer and Hepascore, while oxidative stress is
assessed by measurement of urine and serum F2-
isoprostanes.
Ethics and dissemination: This study has been
approved by the Human Research Ethics Committees
of Austin Health, Royal Melbourne Hospital and Royal
Brisbane and Women’s Hospital. Study findings will be
disseminated through peer-reviewed publications and
conference presentations.
Trial registration: Trial identifier: NCT01631708;
Registry: ClinicalTrials.gov
INTRODUCTION
Hereditary haemochromatosis (HH), an iron
overload disorder, is the most common
genetic condition in Northern Europeans
among whom approximately 1 in 200 are
homozygous for the HFE p.C282Y amino
acid substitution, the cause of most HH. Not
all p.C282Y homozygotes develop morbidity.1
About 20% of males and 40% of females
with this genotype do not develop iron over-
load.2 At least 28% of males and 1% of
females develop iron overload-related disease
such as liver cirrhosis, diabetes mellitus
and cardiomyopathy.2 These individuals
generally have severe iron overload as indi-
cated by a serum ferritin (SF) of greater than
1000 µg/L. Therefore, the question arises as
to whether the largest group of p.C282Y
homozygotes, those with raised SF but SF less
than 1000 µg/L (defined here as moderate
iron overload), require venesection treat-
ment to normalise SF. Answering this ques-
tion is important since if treatment is
beneficial, introduction of community
screening for HH should be considered
whereas if there is no benefit from treat-
ment, p.C282Y homozygotes with moderate
iron overload do not need to undertake this
somewhat onerous intervention.
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Major management guidelines for HH recommend
treatment of those with HH and SF above the upper limit
of normal and recommend that SF be reduced to 50–
100 µg/L.3 4 The rationale for normalisation of SF in
those with severely elevated SF (>1000 µg/L) is clear as
severe morbidity and mortality can be prevented.5 6 There
is little evidence that treatment is beneficial in those with
moderate iron overload however. There have been no ran-
domised controlled trials to objectively assess whether
returning iron levels to normal improves symptoms in p.
C282Y homozygotes with moderately elevated SF. Reasons
why such studies have not been carried out likely include
the fact that treatment of HH is relatively safe and there-
fore commentators have adopted the stance that treatment
is unlikely to result in harm while there are theoretical
reasons why harm may result from not normalising SF.7 In
addition, blinding is far more complex in a trial of vene-
section than in a placebo-controlled pharmaceutical trial.
HFE p.C282Y homozygotes with moderately elevated SF
do not have an increase in frequency of HH-related symp-
toms when compared to controls in cross-sectional
studies.8 9 Such cross-sectional studies are not designed to
identify subtle symptoms such as fatigue, however.
Anecdotal evidence suggests that fatigue benefits from
treatment of HH. Fatigue is a non-specific symptom that is
commonly reported in individuals with HH2 10–13 and has
a negative impact on the physical and psychological
quality of life.14 There are conflicting data about the rela-
tionship between fatigue and levels of excess iron. Adams
et al10 found an association between fatigue and hepatic
iron index in 410 p.C282Y homozygotes. In contrast,
fatigue has been reported in p.C282Y homozygotes with
normal SF13 15 and has been found to be worse in some
individuals following normalisation of SF by venesection
treatment.11 15 One population study identified signifi-
cantly higher Modified Fatigue Impact Scale (MFIS)
scores in p.C282Y homozygotes who knew their diagnosis
and had their iron levels normalised compared to those
who were unaware of the diagnosis and had significantly
higher SF.2 There are three possible explanations for these
observations: (1) There is no relationship between fatigue
and iron levels in HH; (2) there is a significant psycho-
somatic effect of diagnosis on how these individuals per-
ceive fatigue; or (3) there is a subgroup of individuals who
have fatigue and are more likely to be diagnosed with HH.
A recent study suggested that treated HFE p.C282Y
homozygotes with moderate iron overload have
decreased cardiovascular and extrahepatic cancer-
related mortality rates compared to the general popula-
tion, while p.C282Y homozygotes with normal SF have
the same mortality rates as the general population.7 The
relationship between the mortality findings and treat-
ment of iron overload was questioned, however.16
AIMS AND HYPOTHESIS
The aim of this multicentre randomised trial is to
compare the prevalence of symptoms and objective
markers of disease between those in the treatment
group and those in the sham treatment group.
Our hypothesis is that HFE p.C282Y homozygotes with
moderately elevated SF will have few symptoms and signs
of disease and decreasing SF to normal levels will not
result in a greater change in patient reported outcomes
or objective markers of liver injury or hepatic fibrosis
compared to those whose SF levels are not lowered to
the normal range.
METHODS AND ANALYSIS
The Mi-iron (Moderately increased iron levels) study is a
multicentre, randomised single-blinded trial being con-
ducted in Victoria (Austin Hospital and the Royal
Melbourne Hospital) and Queensland (Royal Brisbane
and Women’s Hospital) that started in August 2012 and
is due to conclude in December 2015. Figure 1 sum-
marises the methodology of the Mi-iron Study.
Participants
Inclusion criteria
1. Age 18–70 years inclusive
2. HFE p.C282Y homozygous
3. SF between 300 and 1000 μg/L
4. Previously or currently raised TS
Exclusion criteria
1. HH due to other genotypes
2. Venesection in the past 2 years for treatment of HH
3. Other risk factor(s) for liver injury including hepatitis
B (HBV) or C (HCV), excess alcohol consumption
(>60 g/day in males, 40 g/day in females), body mass
index (BMI) of ≥35 kg/m2
4. Pregnant females
Study intervention
Apheresis is being used as the study intervention. All
procedures are conducted using the Haemonetics MCS
Plus apheresis system.
Randomisation and stratification
Participants are randomised to either the treatment
group to have erythrocytapheresis or the sham
treatment group to have plasmapheresis. Randomisation
is by computer generated random number sequence.
Randomisation is stratified by gender, initial SF
(300–599 μg/L or 600–1000 μg/L as a binary variable)
and site.
Maintenance of blinding
The participant is blinded as to which arm of the study
he/she has been randomised by being connected to the
apheresis machine with the machine and the tubing not
visible to the individual. This is achieved by the partici-
pant’s arm being passed through an opaque black
curtain (figure 2). Thus participants are unaware of
whether they are having red blood cells (RBCs) or
plasma removed and are unaware of whether or not they
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are having their iron levels reduced. Staff performing
the apheresis are trained to not inadvertently reveal the
treatment arm of the participant through strict adher-
ence to study protocol and careful use of language in
describing what is being performed. A member of the
research team is present during the intervention to
ensure blinding is maintained by monitoring the pro-
cedure and conversation between apheresis staff with
the participant.
Those undergoing plasmapheresis have the same
volume of plasma removed as the volume of RBCs
removed had they been randomised to the erythrocyta-
pheresis arm. Therefore, the risk of symptoms due to
reduction in circulating blood volume is the same for
individuals in both arms of the study.
Intervention
Treatments are administered every 3 weeks. The volume
of RBCs/plasma removed is individualised based on the
individual’s blood volume and haematocrit. Haematocrit
is measured at the start of each erythrocytapheresis
treatment while in the sham treatment group, mock
blood tests are taken to ensure the participant’s experi-
ence is identical irrespective of the treatment group to
which they have been randomised. The volume removed
is calculated based on the height, weight, pretreatment
haematocrit and the target haematocrit (30–35%; figure
3). Treatments are ceased in the treatment group when
SF is below 300 µg/L. For the sham group, the calcu-
lated number of treatments is equivalent to as if their SF
was normalised in the RBC group.
Participants in the sham arm are offered erythrocyta-
pheresis or phlebotomy to normalise SF at their choice
of venue on completion of the study.
Safety blood test monitoring
All participants have SF measured 2–3 weeks after the
expected last treatment to ensure the SF level has
decreased to the normal range (<300 µg/L) for those in
the treatment group before proceeding to the end of
trial assessment. Participants in both arms of the study
have the same blood test to ensure blinding. Serum B12,
Figure 1 Flow chart of
methodology for the Mi-iron
Study. TS, transferrin saturation;
SF, serum ferritin; MFIS, Modified
Fatigue Impact Scale; SF36v2,
Medical Outcomes Study 36-item
short form V.2; HADS, Hospital
Anxiety and Depression scale;
AIMS2-SF, Arthritis Impact
Measurement Scales 2 short
form; TE, transient elastography.
Ong SY, et al. BMJ Open 2015;5:e008938. doi:10.1136/bmjopen-2015-008938 3
Open Access
group.bmj.com on February 11, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
folate, iron studies and full-blood count are checked
approximately mid-treatment in both groups for safety
monitoring.
Target SF
There have been no definitive studies conducted to
demonstrate what the target SF should be at the end of
treatment in an individual with HH. Guidelines recom-
mend a target SF of less than 50–100 μg/L. In this study,
we have chosen to reduce SF to anywhere in the normal
range, that is, a SF of 20–300 μg/L, based on the expect-
ation that an individual with HH whose SF is in the
normal range should have similar symptoms to those
without HH and who have a normal SF.
Outcome measures
The outcome measures being assessed are patient-
reported outcome scales to assess symptoms, as well as
markers of liver injury, hepatic fibrosis and oxidative
stress. These are administered at baseline and the end
of erythrocytapheresis/ sham apheresis treatment.
Patient-reported outcome scales
1. Modified Fatigue Impact Scale (MFIS) is the primary
outcome measure for this study. The MFIS is a
21-item scale that measures the impact of fatigue on
three independent subscales of physical, cognitive
and psychosocial functioning.18 Participants rate
their fatigue in the past month on a five-point
Likert-type scale. The total score ranges from 0 to 84
with higher scores reflecting greater fatigue. Subscale
scores, physical (0–36); cognitive (0–40); and psycho-
social (0–8), can also be derived.
2. Medical Outcomes Study 36-item short form V.2 (SF36v2)
is a 36-item generic health survey to measure health
and well-being19 that has been previously used in
various HH studies to measure quality of life.2 12 20 21
It assesses eight different health components (phys-
ical functioning, role-physical, bodily pain, general
health, vitality, social functioning, role-emotional,
mental health) and provides a summary score for
both physical and mental components. It is a norm-
based scoring system and thus can be used to
compare participant scores to the general
population.
3. Hospital Anxiety and Depression Scale (HADS) is com-
posed of a 14-item total scale (HADS-T) consisting of
two seven-item independent subscales, the Anxiety
(HADS-A) and Depression (HADS-D) subscales.22
Participants rate how they have felt in the past week
on a four-point Likert-type scale. Scores on each scale
can be interpreted in ranges: normal (0–7); mild (8–
10); moderate (11–14); and severe (15–21). Higher
scores on each subscale or the entire scale indicate
Figure 3 Equation to estimate
postcollection haematocrit (Hct
post) based on total blood volume
(TBV) using Nadler’s fomula.17
Adopted from the Haemonetics
MCS Plus apheresis system
manual. TBV, total blood volume;
RBC, red blood cell; Hct,
haematocrit.
Figure 2 A black opaque curtain prevents the participant from seeing the apheresis machine and therefore the individual cannot
see if red blood cells or plasma is removed. (A) View from the patient’s perspective, (B) View from the apheresis machine side of
the curtain.
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greater anxiety, depression or both. This scale has
been found to be valid and reliable in various
populations.23 24
4. Arthritis Impact Measurement Scales 2 short form
(AIMS2-SF) is a 26-item validated scale that assesses
the impact of arthritis on five core domains of the
participants.25 26 It measures physical functioning,
symptoms, affect, role and social interactions of the
individuals. A five-point Likert-type scale is used to
rate how participants have felt in the past month.
The higher the raw score, the greater the impact of
arthritis on the participant. Use of arthritis medica-
tion at baseline and end of trial will also be
compared.
5. To assess the fidelity of the blinding process, the par-
ticipants are asked which treatment group they
believe they were allocated to at the completion of
the study, before unblinding.
Liver injury and hepatic fibrosis markers
Transient elastography (TE) and blood tests for compo-
nents of Hepascore and Fibrometer3G V are collected
from individuals at baseline and end of the trial.
Transient elastography
Fibroscan is a method of TE that evaluates liver stiffness
using an ultrasound probe to measure the velocity of a
mechanical wave that is pulsed through the liver. As the
liver becomes progressively more fibrotic, it becomes
harder and less elastic. The velocity of the wave corre-
lates directly with tissue stiffness and results are reported
in kilopascals (kPa).27 TE has been evaluated in a
number of different liver diseases, including HBV and
HCV, alcoholic liver disease, non-alcoholic fatty liver
disease and HH.28 29 A recent meta-analysis of nine
studies involving TE showed excellent results for diag-
nosing cirrhosis, with a sensitivity of 87% and specificity
of 91%.30 Adhoute et al31 have shown that TE measure-
ments correlate with Hepascore measurements in indivi-
duals with HH. The results of liver stiffness are acquired
from at least 10 successful valid measurements with a
success rate of at least 60% within the IQR of ≤30%. A
cut-off value of 8.7 kPa was sensitive for the diagnosis of
those with significant fibrosis (≥F2), with an area under
the curve (AUC) for the receiver operating characteristic
(ROC) of 0.7932 and a reading of more than 13 kPa was
highly predictive that cirrhosis of the liver was present in
a cohort with iron overload due to β-thalassaemia.33
Hepascore
Hepascore is derived from an age-specific and gender-
specific model that inputs parameters of serum biliru-
bin, γ glutamyl transferase (GGT), hyaluronic acid and
α2-macroglobulin. The test results in a score between 0
and 1 with a higher score being associated with more
severe liver disease. In a HCV cohort, Hepascore
demonstrated an AUC for the ROC of 0.8 for predicting
significant fibrosis (≥F2) and 0.90 for predicting
cirrhosis.34 A score >0.5 was found to have a specificity
of 70% and sensitivity of 77% to detect significant fibro-
sis (≥F2) in a large HCV cohort.35 A Hepascore <0.25
can exclude significant fibrosis with a negative predictive
value of 0.9.35 In a study that included the Hepascore in
HFE related HH, 44 p.C282Y homozygotes had a median
score of 0.1.36
Fibrometer3G V
Fibrometer3G V is formulated from the platelet count
(PLT), prothrombin index (PI), and the alanine amino
transaminase (ALT), aspartate amino transaminase
(AST), GGT, α2-macroglobulin and urea levels. This bio-
marker had an AUROC of 0.85 for predicting significant
fibrosis and an AUROC of 0.9 for predicting cirrhosis in
a HCV cohort.37 Its robustness has been evaluated in dif-
ferent studies and has been recommended by the
French National Authority for Health for the estimation
of liver fibrosis in HCV.
The combination of Fibrometer3G V and TE has
recently been shown to increase the accuracy of diagnos-
ing significant fibrosis and cirrhosis to 92% compared
with Fibrometer3G V (84% accuracy) or TE (88% accur-
acy) alone. The combination has an AUROC of 0.89,
improving the reliability and precision of diagnosis of
significant fibrosis in chronic liver disease.38 39
Fibrometer has not been tested in HH.
Oxidative stress marker
Iron is a strong pro-oxidant and there is evidence that
markers of oxidative stress are elevated in individuals
with elevated iron indices due to HH.40–43 To assess oxi-
dative stress, F2-isoprostanes, a validated marker of cellu-
lar lipid oxidative damage,44 are being measured in
urine and blood. While elevated makers of oxidative
stress are not necessarily related to symptoms of disease,
we will be able to assess the relationship between this
early marker of tissue injury and the other markers
being measured, including iron indices, Hepascore,
Fibrometer, TE score and the scores for the various clin-
ical scales being administered. We will also assess
whether F2-isoprostanes are positively impacted by nor-
malisation of iron indices in the erythrocytapheresis
group.
Sample size calculation
Data from the Melbourne HealthIron study2 were used to
calculate SDs of the MFIS score of 14.1 and 17.8 for male
and female C282Y homozygotes, respectively. Using a
conservative value for the SD of 18, a sample size of 50 in
each treatment group ensures an 80% chance (statistical
power) that a treatment effect of a mean difference of 10
MFIS units (well above a clinically relevant difference on
this scale which runs from 0 to 84) is reflected in a p
value less than 0.05. Summary statistics from figure 2 of
Adams et al34 show the mean Hepascore changing from
0.20 in patients with METAVIR fibrosis grade 0 or 1 (F0
or F1), through 0.45 in those with F2, to close to 1.0 in
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those with F3 or F4. The within-fibrosis grade SD of
Hepascore is approximately 0.20 in the F2 group and it is
much lower in the remaining groups. Using this SD, a
sample size of 50 in each treatment group of the trial deli-
vers statistical power of 85% to detect a treatment effect
of 0.12 on the Hepascore scale. A change of this magni-
tude is similar to the observed mean difference in
Hepascore between adjacent fibrosis groups presented in
Adams et al.34 Accommodating the stratified design, the
regression-based statistical analysis will result in minimal
loss of power provided that only the average initial mea-
sures and not the treatment effects are different between
strata.
Statistical analysis
The primary analysis addressing the research hypothesis
will be a comparison of the change in scores for all
outcome scales, biochemical tests and TE scores, from
baseline to end of treatment, between those who have
had their iron levels returned to normal and those who
were in the sham treatment group, with assignment to
the comparison groups based on intention to treat. This
analysis will be implemented using a linear regression
model of the final measure on each scale including as
covariates the value of the initial measure, gender, initial
SF (300–599 μg/L or 600–1000 μg/L as a binary variable)
and site (Melbourne or Brisbane as a two category vari-
able). In a separate analysis, this model with the
Hepascore as the outcome measure will be extended to
include the quantity of iron removed (calculated as 1 g
iron per litre of RBCs removed by erythrocytapheresis) to
determine whether there is an association between the
change in Hepascore and the reduction in iron level.
Similar analyses will be performed for F2-isoprostanes,
TE and patient-reported outcome scales.
CONCLUSION
This is the first randomised controlled trial of treatment
for HH. It will demonstrate whether there is any benefit
in the short term from normalisation of SF in HFE p.
C282Y homozygotes with moderately elevated SF. This
has implications for management of this group of indivi-
duals and may assist in determining whether introduction
of community screening for HH should be considered.
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